GSK’s Voltaren Arthritis Pain Receives the US FDA’s Approval as an OTC Medication

 GSK’s Voltaren Arthritis Pain Receives the US FDA’s Approval as an OTC Medication

GSK’s Voltaren Arthritis Pain Receives the US FDA’s Approval as an OTC Medication

Shots:

  • The US FDA has approved Voltaren Arthritis Pain (diclofenac sodium topical gel, 1%) as an OTC for the temporary relief of arthritis pain in the hand, wrist, elbow, foot, ankle or knee in adults aged ≥18yrs.
  •  The approval is based on a clinical study assessing Voltaren Arthritis Pain in patients with OA in hand & knee supporting the original prescription approval. The study demonstrated the onset of pain relief beginning as early as 1wk.
  • Following the approval, Voltaren Arthritis Pain becomes the first and only prescription-strength, NSAID topical gel for arthritis pain to be available as OTC in the US

Click here ­to­ read full press release/ article | Ref: GSK  | Image: Voltaren

Tuba Khan

Tuba Khan is an Editor and Digital Marketing expert at PharmaShots. She is curious, creative, and passionate about recent updates and innovation in Lifesciences industry. She covers Pharma, Medical devices, Diagnostics and Digital health segment. Tuba also has an experience of digital and social media marketing and can run the campaign independently. She is also certified as a Digital marketer and social media marketer. She can be contacted on tuba@pharmashots.com

Related post